Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies
|
|
- Susan Stewart
- 5 years ago
- Views:
Transcription
1 Ann. N.Y. Acad. Sci. ISSN ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: The Year in Diabetes and Obesity Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies Sophia Zoungas 1,2 and Anushka Patel 3 1 Diabetes Research Program, Cardiovascular Division, The George Institute for International Health, University of Sydney, Sydney, Australia. 2 School of Public Health, Monash University, Melbourne, Australia. 3 Cardiovascular Division, The George Institute for International Health, University of Sydney, Sydney, Australia Address for correspondence: Sophia Zoungas, The George Institute for International Health, King George V Building, Royal Prince Alfred Hospital, PO Box M201, Missenden Road, NSW 2050, Australia. szoungas@george.org.au The world is facing an unprecedented increase in type 2 diabetes. Most disability and premature mortality experienced by people with diabetes is related to cardiovascular disease. This review summarizes recent evidence about approaches for managing cardiovascular risk in patients with type 2 diabetes. While optimal blood pressure targets in people with diabetes remain uncertain, new data have demonstrated the benefits of routine blood pressure lowering in these patients, when administered without regard to initial blood pressure level. Other recent data indicate that blood pressure lowering treatment in patients with diabetes needs to be continued for ongoing benefit. The effects of intensive blood glucose lowering have been evaluated recently in a number of large trials, and individually these have failed to provide evidence of cardioprotection over a 4 5 year period. However, longer-term follow-up data suggest that there may be a delay in any such benefits becoming apparent. The benefits of statin therapy in preventing cardiovascular events in diabetic patients have been recently confirmed in a systematic overview of relevant trials; however, effects of fibrate therapy appear more limited. The role of antiplatelet agents remains unknown, as adequately powered trials of aspirin for the primary prevention of cardiovascular events in patients with diabetes have not yet been completed. Keywords: type 2 diabetes; cardiovascular disease; preventive therapies The prevalence of type 2 diabetes is rapidly rising worldwide. 1 Most disability and premature mortality in patients with diabetes is caused by vascular complications in particular, coronary artery disease and stroke. Indeed in 2010 in those aged years, around 4 million deaths globally will be attributable to diabetes, with 50% of those due to cardiovascular disease. 1 Therefore, many approaches to improve clinical outcomes in patients have continued to focus on the prevention of cardiovascular events. In this review, we focus on the major strategies utilized for the delay or avoidance of cardiovascular events in patients with diabetes blood pressure lowering, blood glucose lowering, lipid modification, and antiplatelet therapy and provide a summary of the most recent evidence relating to the effects of these interventions. Blood pressure lowering A target blood pressure level of 130/80 mmhg or lower, using an initial regimen including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), is recommended by current hypertension guidelines for patients with diabetes. 2 While observational data showing a continuous association between blood pressure and cardiovascular risk suggests potential benefits of more intensive blood pressure lowering for people with diabetes, 3 direct randomized trial evidence about appropriate targets has been lacking. Debate about the relative benefits of particular therapeutic regimens for blood pressure lowering in diabetic patients is also ongoing. A number of major trials have recently addressed these issues. doi: /j x Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences. 29
2 ADVANCE The Action in Diabetes and Vascular Disease Prelerax and Diamicron MR Controlled-Evaluation (ADVANCE) trial was a factorial, randomized study of 11,140 individuals with type 2 diabetes from over 200 collaborating centers in 20 countries from Asia, Australasia, Europe, and North America. 4,5 Participants with either a history of macrovascular or microvascular disease, or at least one major risk factor for cardiovascular disease and any initial level of blood pressure and blood glucose, were randomly assigned to the fixed combination of the ACE inhibitor, perindopril and the thiazide diuretic, indapamide (4/1.25 mg) or matching placebo, and to intensive glucose control or standard guidelinebased glucose control. 4,5 The primary outcomes were composites of major cardiovascular (nonfatal acute myocardial infarction, nonfatal stroke, and cardiovascular death) and major microvascular events (new or worsening nephropathy and microvascular eye disease), analyzed jointly and separately. The average duration of follow-up was 4.3 years for the blood pressure lowering intervention, and 5.0 years for the glucose control intervention. 4,5 Importantly, in the blood pressure arm, ADVANCE was testing the effects of a strategy of routinely administering blood pressure lowering therapy to individuals with diabetes at high risk of a cardiovascular event, regardless of initial blood pressure level. This trial was not designed to evaluate different target blood pressure levels. The mean entry blood pressure of participants was 145/81 mmhg, with over 40% recording a blood pressure below 140/90 mmhg. 5 Over the course of active treatment, blood pressure was reduced by a mean of 5.6/2.2 mmhg compared to placebo. At the end of follow-up, the mean blood pressure achieved was 134.7/74.8 mmhg in the active treatment group and 140.3/77.0 mmhg in the placebo group. Active treatment reduced the risk of the combined composite primary outcome of major macrovascular and microvascular events by 9% (95% CI 0 to 17%, P = 0.043). Considered individually, the effect on major macrovascular events was of similar magnitude but not statistically significant (Fig. 1). Among those on active treatment, there was a 14% (2 to 25%; P = 0.025) reduction in all-cause mortality, driven by an 18% (2 to 32%; P = 0.027) reduction in cardiovascular mortality, as well as reductions in coronary events (14%; P = 0.02) and renal events (21%; P = ). There were no statistically significant reductions observed in cerebrovascular events or in microvascular eye disease. There was no evidence of heterogeneity in treatment effect in subgroups of participants defined by key baseline characteristics including baseline age, gender, history of cardiovascular disease, and use of blood pressure lowering therapy. In particular, the effects of the combination ACE inhibitor and diuretic treatment were similar across a range of initial blood pressure level and regardless of use of other concomitant preventive therapies (including other blood pressure lowering agents, statins and aspirin). The results of this part of the ADVANCE study point to the potential benefits of an alternative strategy for delivery of blood pressure lowering treatment, as opposed to traditional threshold and target-driven strategies where therapy is limited to patients with arbitrarily-defined hypertension and therefore potentially denied to a broader range of high-risk individuals with apparently normal blood pressure levels. The Action to Control Cardiovascular Risk in Diabetes The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was a factorial study of 10,251 individuals with type 2 diabetes from 77 centers in North America. 6 8 Participants with a HbA1c of 7.5% or more and aged 40 years of age or older with cardiovascular disease or 55 years of age or older with anatomical evidence of significant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least two additional risk factors for cardiovascular disease (dyslipidemia, hypertension, smoking, or obesity) were randomized to intensive glucose control (aiming for HbA 1c levels 6.0%) or standard control (aiming for HbA 1c levels %). 7 Participants were also randomized to either a blood pressure lowering intervention (n = 4733) or lipid management intervention (n = 5518). 6,8 The aim of the blood pressure arm was to examine the effects of targeting different blood pressure levels (a systolic blood pressure target of 120 mmhg or less as compared to 140 mmhg or less). 6 As such, participants who had a systolic blood pressure between 130 and 180 mm Hg on three or fewer antihypertensive medications and no evidence of greater than 1.0 g per day of proteinuria or equivalent, were studied. The blood pressure lowering regimen was at 30 Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences.
3 Figure 1. Effects of routine blood pressure lowering and intensive glucose control on clinical outcomes in the ADVANCE trial. Per-Ind, Perindopril-indapamide. Black squares = point estimates (with area proportional to number of events); horizontal lines = 95% CI. the physician s discretion but included any class of drug therapy known to produce cardiovascular benefits (ACE inhibitor, ARB, diuretic, calcium channel blocker, or beta-blocker). The primary outcome was a composite of major cardiovascular events defined as nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death. 6 8 Secondary outcomes included all coronary events, all stroke events, and all-cause death, considered separately. The mean entry blood pressure was 139/76 mmhg with 87% of participants already taking some from of antihypertensive therapy. 6 Over a mean follow up of 4.7 years, intensive therapy achieved a systolic pressure of 119 mmhg as compared with 134 mmhg in the standard therapy group. Despite this very substantial difference in systolic blood pressure, intensive therapy did not result in a statistically significant reduction in major Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences. 31
4 Figure 2. Effects of intensive versus standard blood pressure control on major cardiovascular outcomes in the ACCORD trial (reproduced with permission from Cushman et al. 6 ). cardiovascular events (relative risk reduction [RRR], 12% 95% CI 6 to 27%, P = 0.20; Fig. 2). When the components of the composite outcome were considered separately, intensive therapy did significantly reduced all major strokes by 41% (95% CI 11 to 61%), but not all major coronary events (which included unstable angina) or cardiovascular death. There was no statistically significant effect of intensive therapy on all-cause mortality or heart failure. There was no evidence of heterogeneity in treatment effect in subgroups of participants defined by baseline age, gender, history of cardiovascular disease, and use of blood pressure lowering therapy. Much has been made of ACCORD being a negative trial with respect to the blood pressure lowering arm. However, notwithstanding the clear benefits of a more aggressive approach to blood pressure lowering for stroke, the confidence intervals around the estimates of effect size for other cardiovasculareventsdonotexcludemoderate(approximately one-quarter reduction) beneficial effects. The event rates in this trial were about one-half those anticipated, 6 resulting in a substantially underpowered study. The United Kingdom Prospective Diabetes Study Over a decade ago, the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that more intensive blood pressure lowering (with an ACE inhibitor or a beta-blocker based regimen) among newly diagnosed patients with type 2 diabetes and hypertension resulted in significant reductions in all diabetes-related endpoints, as well as cerebrovascular events and microvascular disease. 9 Subsequently, annual follow-up for an additional 6 years was undertaken for all study participants, without attempting to maintain therapies based on the original randomization. 10 As a result, the achieved blood pressure difference between randomized arms was no longer apparent within 2 years of the longer-term follow-up. The significant reductions in clinical events were also lost during the additional observational period, without the emergence of any new benefits (Fig. 3). A reasonable interpretation of these findings is that blood pressure reduction needs to be maintained in order for the long-term benefits of such treatment to continue. Other relevant trials While not restricted exclusively to patients with diabetes, the results of two other recent trials provide some evidence about the potential merits of different blood pressure lowering regimens in diabetic patients. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) included 25,620 patients at increased cardiovascular risk, of whom about 40% had diabetes. 11 Patients were randomized to ramipril alone, telmisartan alone, or both drugs. The mean blood pressure level at baseline was 142/82 mmhg, and compared to the ramipril alone group, blood pressure was reduced by 2.4/1.4 mmhg in the combination therapy group over the follow-up period. There was no difference in the incidence of the primary outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalized heart failure) between the ramipril-alone group and each of the other groups. As expected, participants randomized to telmisartan alone experienced less cough and angioedema than those allocated ramipril. However, symptoms of hypotension occurred more frequently in the telmisartan group (2.7%) and in the combination group (4.8%), compared with the ramipril alone group (1.7%). Renal dysfunction was observed more often in the combination group. There was no heterogeneity in treatment effects by diabetes status for the primary 32 Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences.
5 Interpretation of recent evidence Blood pressure lowering remains an important strategy for preventing cardiovascular events in patients with diabetes. Aggressive treatment, aiming for a systolic level <120 mmhg, appears to reduce the risk of stroke, but the effects on other cardiovascular outcomes is uncertain. A strategy of routine treatment, without regard to initial blood pressure level, reduced the risks of coronary events, cardiovascular death, and all-cause mortality. Importantly, the long-term observational follow-up of UKPDS confirms the need to maintain blood pressure lowering to realize ongoing benefits of treatment. Figure 3. Effects of tight versus less tight blood pressure control on any diabetes-related endpoint with long-term followup in the UKPDS (reproduced with permission from Holman et al. 10 ) The horizontal axis indicates the year of follow-up, with the hazard ratio (and 95% CI) indicated for each time point. outcome. In summary, the results of ONTARGET confirmed equivalence of the ACE inhibitor and the ARB, but provided no evidence of additional benefit from combination therapy. Another relevant trial is the Avoiding Cardiovascular Events through Combination Therapy to Patients Living with Systolic Hypertension trial. 12 Approximately 60% of the 11,506 high-risk patients with hypertension included in this study were diabetic. Participants were randomized to the ACE inhibitor, benazepril and the calcium channel blocker, amlodipine, or to benazepril, and the diuretic, hydrochlorothiazide (HCT). The mean blood pressure level at baseline was 145/80 mmhg. Over followup, a 0.9/1.1 mmhg lower blood pressure was observed in the benazepril/amlodipine group, compared with the benazepril/hct group. This study was stopped prematurely after a mean follow-up of 3 years, because of an observed 20% reduction in the primary outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after cardiac arrest, and coronary revascularization) in the benazepril/amlodipine group compared with the benazepril/hct group. Again, there was no evidence of heterogeneity based on diabetes status. Blood glucose lowering While long-term cardioprotection with intensive glucose control has been clearly established for patients with type 1 diabetes, 13,14 the benefits in type 2 diabetes have been less certain. For many years, the most reliable evidence about the effects of more intensive glucose control in patients with type 2 diabetes was derived from the UKPDS. 15,16 While this study demonstrated benefits in reducing microvascular events with more intensive glucose control (HbA1c 7.0% vs. 7.9% at the end of follow-up), the findings were inconclusive with respect to cardiovascular events. Despite this, most clinical guidelines adopted recommended target levels for HbA1c of 6.5% or 7.0%, with the express purpose of preventing both microvascular and macrovascular events. The past two years have seen the completion of a number of new large studies that substantially add to the evidence base. ADVANCE As outlined above, ADVANCE was a factorial trial testing two interventions, one of which was intensive blood glucose control. 4 The glucose-lowering regimen for those randomized to intensive glucose control was based on the modified release sulphonylurea, gliclazide-mr, mg daily; however, nonpharmacological approaches, other oral agents, and insulin were recommended to be added, as required, to achieve the target HbA1c of 6.5%. The choice of such additional treatments was left to the discretion of the responsible physician with a step wise up titration of oral therapy followed by introduction of basal insulin advocated. Participants randomized to standard guidelines-based glucose control were permitted to use sulphonylureas (other than gliclazide) and any other available glucoselowering therapy, including insulin. The mean entry HbA1c of participants was 7.5%, with 91% already receiving oral hypoglycemic agents. By the end of follow up of those in the intensive control group and standard control group, Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences. 33
6 Table 1. Effects of intensive versus standard glucose control in the ACCORD trial Intensive N (%) Standard N (%) HR (95% CI) P Primary 352 (6.86) 371 (7.23) 0.90 ( ) 0.16 Secondary Mortality 257 (5.01) 203 (3.96) 1.22 ( ) 0.04 Nonfatal MI 186 (3.63) 235 (4.59) 0.76 ( ) Nonfatal stroke 67 (1.31) 61 (1.19) 1.06 ( ) 0.74 CVD death 136 (2.63) 94 (1.83) 1.35 ( ) 0.02 CHF 152 (2.96) 124 (2.42) 1.18 ( ) % and 59% were receiving sulphonylurea, 74% and 67% metformin, 40% and 24% insulin, and 17% and 11% thiazolidinediones. HbA1c was gradually reduced (over 3 years) with intensive glucose control to result in a mean HbA1c of 6.5% as compared to 7.3% in the standard arm, and produced an average difference during follow-up of 0.7% between the groups. Furthermore, the target HbA1c of 6.5% or less was achieved by 65% of those assigned intensive glucose control as compared to 29% of those assigned standard control. Intensive glucose control reduced the incidence of combined major cardiovascular and microvascular events by 10% (95% CI: 2 to 18%, P = 0.01). This was primarily due to a significant 21% reduction in the incidence of new or worsening nephropathy. There were no separately significant effects of intensive glucose control on any cardiovascular outcome or death (major cardiovascular events RRR 6%; 95% CI: -6 to 16%; P = 0.32; cardiovascular mortality, RRR 12%, 95% CI: 4 to 26, P = 0.12); or all cause mortality (RRR 7%; 95% CI: -6 to 17; P = 0.28; Fig. 1). The treatment effects were consistent across a range of participant subgroups defined by key baseline characteristics including duration of diabetes and prior history of cardiovascular or microvascular disease. ACCORD As previously outlined, all 10,251 participants in this trial were randomized to intensive glucose control (aiming for HbA 1c levels 6.0%) or standard control (aiming for HbA 1c levels %). 7 To achieve intensive glucose control, therapy was titrated monthly for 4 months and 2 monthly thereafter to achieve and maintain the proposed risk factor target. In the standard control group, therapy and targets were reviewed every 4 months. At study entry, the mean HbA1c of participants was 8.3%, with 34% already receiving insulin therapy. By the end of follow up of those in the intensive control group and standard control group, 87% and 74% were receiving secretagogues, 95% and 87% metformin, 77% and 55% insulin, and 92% and 58% thiazolidinediones. HbA1c was rapidly reduced (within 6 months) with intensive glucose control to achieve a median HbA1c of 6.4% as compared to 7.5% with standard control, representing a mean difference of 1.1%. After an average of 3.5 years follow-up, the trial was terminated prematurely, due to an increased risk of all-cause and cardiovascular mortality in the intensive control group (Table 1). There was no significant difference between the randomized groups in the incidence of the primary composite cardiovascular outcome (RRR 10%; 95% CI: 4 to 22%; P = 0.16). However, nonfatal myocardial infarction was significantly reduced with intensive glucose control (RRR 24%; 95% CI: 8 to 38%); P = 0.004). There was also some evidence of heterogeneity in the treatment effects across participant subgroups, with greater beneficial effects on the cardiovascular outcome in those with a lower entry HbA 1c level (P for heterogeneity = 0.03) and in those without a history of cardiovascular disease (P for heterogeneity = 0.04). The Veterans Affairs Diabetes Trial TheVeteransAffairsDiabetesTrial(VADT)wasalso designed to evaluate the effects of intensive glucose control in patients with type 2 diabetes albeit with substantially less power than the ADVANCE and ACCORD studies. 17 A total of 1,791 U.S. military veterans were randomized, with intensive glucose control resulting in a median HbA1c of 6.9%, as 34 Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences.
7 Figure 4. Effects of intensive versus standard glucose control on myocardial infarction in the UKPDS (reproduced with permission from Holman et al. 18 ) The horizontal axis indicates the year of follow-up, with the hazard ratio (and 95% CI) indicated for each time point. compared to 8.4% in the standard control group (mean difference 1.5%). The incidence of the primary outcome (myocardial infarction, stroke, cardiovascular death, heart failure, surgery for vascular disease, inoperable coronary disease, and amputation for ischemic gangrene) was not significantly different between randomized groups. UKPDS In contrast to the findings of the BP arm of the UKPDS, long-term post-trial observational followup of the glucose-lowering arm demonstrated sustained, and in some cases newly emerged, reductions in clinical events associated with original randomization to intensive glucose control. 18 These benefits were observed despite convergence of HbA1c values within a year of post-trial monitoring. In addition to persistent benefits for microvascular events, a significant reduction in all-cause mortality became apparent at 10 years. Furthermore, the previously borderline nonsignificant 16% relative risk reduction in myocardial infarction observed at the end of the trial became statistically significant at 10 years follow-up (Fig. 4). Interpretation of recent evidence Assuming the finding of excess mortality in ACCORD was not a chance result, a number of other potential reasons for this observation could be considered. For example, the aggressive strategy for intensive glucose control utilized in ACCORD, with implementation of regimens using multiple oral agents and insulin, has been contrasted with that of ADVANCE, which used a much more incremental approach with progressive intensification over a long period. The effects of these different approaches are reflected in the substantially higher proportions of intensive control patients from ACCORD taking insulin (77%) and thiazolidinediones (92%), compared to those in ADVANCE (40% and 19%, respectively, by the end of followup). As a consequence of these differences, the decline in HbA1c occurred much more rapidly in ACCORD, compared to ADVANCE. Furthermore, the rate of severe hypoglycemia (using similar definitions) in ACCORD was sixfold greater than that in ADVANCE. While there was no weight gain among intensive glucose control patients in ADVANCE, those in ACCORD experienced an average 3.5 kg increase in weight over the duration of follow-up. Thus, the method of achieving intensive glucose lowering, rather than the target levels per se may be important. In this context, there has been much discussion about the potential adverse effects of thiazodinidiones in particular, although the design of these strategy trials precludes any reasonable analyses that might tease out the effects of individual drugs. While much focus of interest has been on the apparent increase in mortality with intensive glucose control reported in the ACCORD trial, the totality of evidence raises questions about the robustness of this finding. A recent meta-analysis of ADVANCE, ACCORD, VADT, and UKPDS, conducted by the investigators of these trials, concluded that intensive glucose control in patients with type 2 diabetes was associated with an overall modest one-tenth reduction in major cardiovascular events, primarily due to a 15% relative risk reduction of myocardial infarction (Fig. 5). 19 All-cause and cardiovascular mortality did not significantly differ between groups, with hazard ratios for intensive vs. standard glucose control of 1.04 (95% CI: ) and 1.10 (95% CI: ), respectively. In summary, the effects of blood glucose control have been addressed in a number of recently concluded clinical trials; individually, these have failed to provide clear evidence of cardioprotection with intensive glucose control over a 3 5 year period. However, when pooled together, significant benefits on major cardiovascular events and specifically acute myocardial infarction were evident. Moreover, long-term follow-up data suggest that such benefits may accrue over time and emerge many years Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences. 35
8 Figure 5. Pooled effects of more- versus less-intensive glucose control in major trials (reproduced with permission from Turnbull et al. 19 ). Black squares = point estimates (with area proportional to number of events); horizontal lines = 95% CI. later, indicating that better glycemic control could be cardioprotective over the lifespan of a patient with diabetes. Lipid modification The role of statins for the prevention of cardiovascular events is well established. Robust data related to the use of statins in patients with diabetes, have recently been published by the Cholesterol Treatment Trialists Collaboration. 20 This metaanalysis included 14 randomized trials of statin therapy, and clearly demonstrated that the proportionate benefits of statins in reducing all-cause mortality, vascular death, and cardiovascular events were similar among participants with diabetes (n = 18,686) and without diabetes (n = 71,370). The overview did not identify any subgroup of patients with diabetes where the treatment effects varied. The role of fibrates for prevention of cardiovasculareventsintype2diabetesislessclear.the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial published several years ago, randomized 9,795 patients with type 2 diabetes to fenofibrate or placebo. 21,22 The primary outcome, a composite of coronary death or nonfatal myocardial infarction, was not significantly different between randomized groups after an average of 5 years follow-up. This result reflected a significant 24% reduction in nonfatal myocardial infarction and nonsignificant increase in coronary death, associated with fenofibrate. The study was hampered by a substantial drop-in of statin therapy during follow-up that was greater in the placebo group. More recently, the lipid arm of the ACCORD trial has been reported. 8 In this part of the study, 5,518 patients concurrently taking open-label simvastatin were randomized to fenofibrate or placebo. After a mean follow-up period of 4.7 years, the incidence of the primary composite cardiovascular outcome was similar between randomized groups. Subgroup analysis suggested possible heterogeneity of treatment effects with beneficial effects of fibrates in patients with a baseline lipid profile of low HDL cholesterol and high triglycerides; however, the P value for interaction was of borderline significance. While FIELD and ACCORD represent the largest and most recent trials of fibrates in patients with diabetes, a number of smaller studies with agents other than fenofibrate have been conducted in populations with and without diabetes. A systematic overview of these trials indicated that fibrates were associated with modest but significant reductions in major cardiovascular events and coronary events, but there was no evidence of any reductions in cardiovascular death or all-cause mortality (Fig. 6) Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences.
9 Figure 6. Pooled effects of fibrates on major cardiovascular outcomes (reproduced with permission from Jun et al. 23 ). Black squares = point estimates (with area proportional to number of events); horizontal lines = 95% CI. There was no heterogeneity of treatment effects when comparing trials of patients with diabetes with studies of patients without diabetes or mixed populations. Aspirin While the benefits of aspirin in diabetic patients with established cardiovascular disease is unequivocal, the role of antiplatelet agents for the primary prevention of cardiovascular events in patients with type 2 diabetes remains uncertain. 24 Two recent trials have attempted to address this question. However, both studies were substantially underpowered to reliably determine the effects of aspirin in this target population. The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) randomly allocated 2,539 patients to low-dose aspirin on top of usual care or usual care without aspirin, with a median of 4.4 years follow-up. 25 In this open-label study, only 154 primary outcome events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and peripheral vascular events) occurred, with no significant difference between randomized groups (RRR 20%; 95% CI: 10 to 42%; P = 0.16). In a mixed population with type 1 and type 2 diabetes, the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial randomized 1,276 patients with reduced anklebrachial pressure index but no established cardiovascular disease to low-dose aspirin or placebo. 26 After a median of 6.7 years follow-up, there was no difference between randomized groups in the primary outcome of coronary death, stroke death, nonfatal myocardial infarction, nonfatal stroke, or amputation above the ankle for critical limb ischemia. The trial failed to reach its recruitment target and the event rate was lower than anticipated, with post hoc analysis indicating only 70% power to detect a 25% relative-risk reduction from the intervention. In a factorial design, the trial also examined the effects of an antioxidant capsule on the same outcome, with no differences observed between randomized groups. Although both JPAD and POPADAD failed to demonstrate beneficial effects of aspirin in patients with diabetes, the low power in both studies limits any conclusions that can be drawn from their findings. The ongoing A Study of Cardiovascular Events in Diabetes (ASCEND) trial is likely to provide much more definitive evidence on the role of aspirin for the primary prevention of cardiovascular events in people with type 2 diabetes. 27 Multifactorial intervention While most clinical trials evaluate single interventions on cardiovascular outcomes, the effects of these treatments are generally found to be similar regardless of other preventative therapies that participants are taking. In the factorial trials such as ADVANCE and ACCORD, no clear evidence of interaction between treatment strategies has emerged. 6,8,28 Together, these findings indicate that the effects of therapeutic strategies are independent and thus benefits from their combined use should be additive. The Steno-2 study randomized 160 patient with type 2 diabetes and microalbuminuria to intensive multifactorial intervention (tight glucose control, use of renin angiotensin system blockers, Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences. 37
10 aspirin, and lipid lowering agents) or conventional therapy. 29 During the 7.8 year trial period, the risk of vascular complications was halved with multifactorial intervention, compared to standard care. The participants were observed for a further 5.5 years, during which time risk factor differences narrowed, but were persistent. 30 At the end of this observational period, all-cause mortality among intensively treated patients was less than one-half of that observed in the group previously assigned conventional therapy (Fig. 7). Conclusions While cardiovascular disease remains a dominant problem for patients with diabetes, a number of effective preventative strategies are available, with particularly beneficial effects from their combined use. Importantly, the absolute benefits of these treatments will be directly proportionate to the patient s baseline risk, suggesting that most benefit will accrue from more aggressive multifactorial intervention among those at highest risk. Although this review has highlighted some important gaps in our knowledge about cardiovascular risk factor modification in patients with diabetes, the greater challenge lies in effectively implementing existing evidence into routine clinical practice. As the global burden of diabetes continues to expand, developing, implementing, and evaluating new strategies to maximize this implementation is an increasing priority. Figure 7. Multifactorial risk factor management in the STENO trial (reproduced with permission from Gaede et al. 30 ). Panel A: Cumulative incidence curves for all-cause mortality, by treatment allocation; Panel B: Cumulative incidence curves for all cardiovascular events, by treatment allocation; Panel C: Numbers of cardiovascular events by type and treatment allocation. BOX 1: Risk factor modification in type 2 diabetes authors interpretation Blood pressure: Current recommendation for a target systolic blood pressure < 130 mmhg is reasonable based on current evidence, with likely particular benefits in reducing stroke and kidney disease. Blood glucose: Current recommendation for atargethba1c< 7.0% is reasonable if this can be achieved cautiously, with the expectation of reduced risks of kidney disease and probable modest reductions in myocardial infarction risk. Lipid modification: Statin therapy should be considered for all patients, while the addition of fibrates may lead to a modest reduction in nonfatal cardiovascular events, particularly among those with a pattern of atherogenic dyslipidemia. Aspirin: Routine use of low-dose aspirin should be considered in all patients with diabetes and cardiovascular disease or with an equivalent estimated cardiovascular risk 38 Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences.
11 (i.e. 5-year cardiovascular disease risk greater than 20%). The treatment effects of these interventions are independent and thus combined use will result in substantial benefits. Those patients with type 2 diabetes at highest risk will benefit the most in absolute terms, thus risk stratification is useful in influencing the intensity of preventative treatments. Acknowledgments Sophia Zoungas is supported by a Health Practitioner fellowship from the National Health and Medical Research Council of Australia and Royal Australasian College of Physicians. Anushka Patel is supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia. Conflicts of interest The authors declare no conflicts of interest. References 1. International Diabetes Federation, Diabetes Atlas 2009; 4th Ed. 2. Standards of medical care in diabetes Diabetes Care 2009;32(Suppl 1): S13 S Adler, A.I., I.M. Stratton, H.A. Neil, et al Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (Clinical research ed) 321: Patel, A., S. MacMahon, J. Chalmers, et al Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358: Patel, A., S. MacMahon, J. Chalmers, et al Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: Cushman, W.C., G.W. Evans, R.P. Byington, et al Effects of intensive blood-pressure control in type 2 diabetes mellitus. N.Engl.J.Med.362: Gerstein, H.C., M.E. Miller, R.P. Byington, et al Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358: Ginsberg, H.N., M.B. Elam, L.C. Lovato, et al Effects of combination lipid therapy in type 2 diabetes mellitus. N.Engl.J.Med.362: UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ (Clinical research ed) 317: Holman, R.R., S.K. Paul, M.A. Bethel, et al Longterm follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 359: Yusuf, S., H.C. Diener, R.L. Sacco, et al Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med. 359: Jamerson, K., M.A. Weber, G.L. Bakris, et al Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N.Engl.J.Med.359: The Diabetes Control and Complications Trial Research Group Effects of intensive diabetes management on macrovascular disease and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol. 75: The DCCT/EDIC Research Group Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med. 353: UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: Duckworth, W., C. Abraira, T. Moritz, et al Glucose control and vascular complications in veterans with type 2 diabetes. N.Engl.J.Med.360: Holman, R.R., S.K. Paul, M.A. Bethel, et al year follow-up of intensive glucose control in type 2 diabetes. N.Engl.J.Med.359: Turnbull, F.M., C. Abraira, R.J. Anderson, et al Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52: Baigent, C., A. Keech, P.M. Kearney, et al Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: Keech, A., J. Simes, P. Barter, et al Correction to the FIELD study report. Lancet 368: Keech, A., R.J. Simes, P. Barter, et al Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: Jun, M., C. Foote, J. Lv, et al Effects of fibrates on cardiovascular outcomes: a systematic review and metaanalysis. Lancet 375: Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical research ed 2002) 324: Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences. 39
12 25. Ogawa, H., M. Nakayama, T. Morimoto, et al Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300: Belch, J., A. MacCuish, I. Campbell, et al The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a Haynes, R., L. Bowman, J. Armitage Aspirin for primary prevention of vascular disease in people with diabetes. BMJ 339: b Zoungas, S., B.E. de Galan, T. Ninomiya, et al Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32: Gaede, P., P. Vedel, N Larsen, et al Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348: Gaede, P., H. Lund-Andersen, H.H. Parving, O. Pedersen, Effect of a multifactorial intervention on mortality in type 2 diabetes. N.Engl.J.Med.358: Ann. N.Y. Acad. Sci (2010) c 2010 New York Academy of Sciences.
ADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationCANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Diabetes Management Coutts S, Wein T (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2014 Heart and Stroke Foundation November 2014
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationThe New Diabetes Standard of Care: More Than Just Glycemic Control. Copyright
CLINICAL Viewpoint The New Diabetes Standard of Care: More Than Just Glycemic Control Advancement in Diabetes Management: A Canadian Diabetes Steering Committee Report Copyright Not for Sale or Commercial
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationUpdate sulla terapia antiipertensiva e antiaggregante nel paziente cardiometabolico
Update sulla terapia antiipertensiva e antiaggregante nel paziente cardiometabolico G. Mazzanti UO Cardiologia Ospedale SS. Annunziata, Cento (FE) AUSL di Ferrara Antiplatelet therapy Aspirin Aspirin:
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationGlucose Control: Does it lower CV risk?
Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationUpdate on Diabetes. Ketan Dhatariya. Why it s Not Just About Glucose Lowering Any More. Consultant in Diabetes NNUH
Update on Diabetes Why it s Not Just About Glucose Lowering Any More Ketan Dhatariya Consultant in Diabetes NNUH The Story So Far.. DCCT Retinopathy Neuropathy Nephropathy Intensive glucose control in
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDIABETES AND METABOLIC SYNDROME
TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 48,508 20,091 41.4% 61.1 4.3 4/7 (57.1%) HR PROactive (Dormandy et al 61
More informationReview. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction
Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationBLOOD PRESSURE-LOWERING TREATMENT
BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationEffect of Blood Pressure Management on Coronary Heart Disease Risk in Patients with Type 2 Diabetes
4 Effect of Blood Pressure Management on Coronary Heart Disease Risk in Patients with Type Diabetes Anushka A. Patel EPIDEMIOLOGIC ASSOCIATIONS BETWEEN BLOOD PRESSURE AND CORONARY HEART DISEASE IN PEOPLE
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationCANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Diabetes Management Wein T, Gladstone D (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2017 Heart and Stroke Foundation September
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationEducational Objectives
05 MAY 18 William J. Elliott, M.D., Ph.D. Cardiovascular Consequences of Diabetes Disclosure Statement The speaker s research and educational activities have been supported in the past by essentially every
More informationThe Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationSESSION 5 2:20 3:35 PM
SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationThe publication of the U.K. Prospective
D I A B E T E S A N D C A R D I O V A S C U L A R D I S E A S E A Summary of the ADVANCE Trial SIMON R. HELLER, DM, FRCP ON BEHALF OF THE ADVANCE COLLABORATIVE GROUP* The publication of the U.K. Prospective
More informationThis regimen can safely be recommended for patients with type 2 diabetes in all of these regions. Diabetes Care 34: , 2011
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Does Glycemic Control Offer Similar Benefits Among Patients With Diabetes in Different Regions of the World? Results
More informationTop 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008
Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation
More informationNear-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE
Therapeutic Advances in Endocrinology and Metabolism Review Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE Patrick J. O Connor and Faramarz Ismail-Beigi
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationManagement of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Review Advances in CKD 216 Published online: January 15, 216 Management of Hypertension in Diabetic Nephropathy: How Low Should We Go? Hillel Sternlicht George L. Bakris Department of Medicine, Section
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationType 2 diabetes affects 240 million
Pathophysiology/Complications O R I G I N A L A R T I C L E Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationType 2 diabetes affects an estimated 25.8 million
Hosp Pharm 2014;49(8):697 701 2014 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj4908-697 Cardiovascular Therapeutics Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationPractical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua
Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationThe State of Hypertension in NZ in 2010 personal view
The State of Hypertension in NZ in 2010 personal view Patient referred to medical clinic Dear Dr, Please see this man with resistant hypertension 50 year old European male Blood Pressure on current meds
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationEducational and behavioral interventions hitherto published
Treatment of High-Risk Patients with Diabetes: Motivation and Teaching Intervention: A Randomized, Prospective 8-Year Follow-Up Study Rita Rachmani, Inna Slavacheski, Maya Berla, Ronni Frommer-Shapira,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled
Articles MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial Heart Protection Study Collaborative Group* Summary Background
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationUpdate on the Canadian Diabetes Association 2008 clinical practice guidelines
Update on the Canadian Diabetes Association 2008 clinical practice guidelines Onil K. Bhattacharyya MD PhD CCFP Elizabeth A. Estey MA Alice Y.Y. Cheng MD FRCPC Rates of diabetes are increasing in Canada,
More information